ArticlePloS one2015
Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 91 citations in OpenAlex.
- Comparative analysis of selective fungal culture media and incubation conditions forMicrobiology spectrum · 2026Article
- Gut-Lung Axis Microbiome Dysbiosis and Cross-Domain Network Analysis in Bronchiectasis Complicated by Invasive Pulmonary Aspergillosis.Infection and drug resistance · 2026Article
- Migration Characteristics of Manure-Derived Antibiotic-Resistant Bacteria in Vegetables Under Different Soil Types.Microorganisms · 2025Article
- Article
- Article
- Anti-Fungal (Pathogens (Basel, Switzerland) · 2024Article
- The Expanding Mycovirome ofJournal of fungi (Basel, Switzerland) · 2024Review
- Convergent evolution in toxin detection and resistance provides evidence for conserved bacterial-fungal interactions.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Molecular and biological characterization of a novel partitivirus from Talaromyces pinophilus.Virus research · 2024Article
- Antifungal Activity of Brilacidin, a Nonpeptide Host Defense Molecule.Antibiotics (Basel, Switzerland) · 2024Article
- The airway mycobiome and interactions with immunity in health and chronic lung disease.Oxford open immunology · 2024Review
- Molecular and biological characterization of a partitivirus fromThe Journal of general virology · 2023Article
- Interactions between Bacteria andJournal of fungi (Basel, Switzerland) · 2023Review
- Infection, Allergy, and Inflammation: The Role ofMicroorganisms · 2023Review
- The Fungal and Bacterial Interface in the Respiratory Mycobiome with a Focus onLife (Basel, Switzerland) · 2023Review
- Polymycovirus Infection SensitizesViruses · 2023Article
- Simple method for quantification of anionic biosurfactants in aqueous solutions.Frontiers in bioengineering and biotechnology · 2023Article
- Co-Operative Biofilm Interactions betweenJournal of fungi (Basel, Switzerland) · 2022Article
- Exposure to theMicrobiology (Reading, England) · 2022Article
- Metrics of Antifungal Effects of Ciprofloxacin onJournal of fungi (Basel, Switzerland) · 2022Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus fumigatus (Af) and Pseudomonas aeruginosa (Pa) are leading fungal and bacterial pathogens, respectively, in many clinical situations. Relevant to this, their interface and co-existence has been studied. In some experiments in vitro, Pa products have been defined that are inhibitory to Af. In some clinical situations, both can be biofilm producers, and biofilm could alter their physiology and affect their interaction. That may be most relevant to airways in cystic fibrosis (CF), where both are often prominent residents. We have studied clinical Pa isolates from several sources for their effects on Af, including testing involving their biofilms. We show that the described inhibition of Af is related to the source and phenotype of the Pa isolate. Pa cells inhibited the growth and formation of Af biofilm from conidia, with CF isolates more inhibitory than non-CF isolates, and non-mucoid CF isolates most inhibitory. Inhibition did not require live Pa contact, as culture filtrates were also inhibitory, and again non-mucoid>mucoid CF>non-CF. Preformed Af biofilm was more resistant to Pa, and inhibition that occurred could be reproduced with filtrates. Inhibition of Af biofilm appears also dependent on bacterial growth conditions; filtrates from Pa grown as biofilm were more inhibitory than from Pa grown planktonically. The differences in Pa shown from these different sources are consistent with the extensive evolutionary Pa changes that have been described in association with chronic residence in CF airways, and may reflect adaptive changes to life in a polymicrobial environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.